天境生物科技（上海）有限公司 IMab Mediaroom

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-st...

2024-08-26 19:00 886

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as ind...

2024-08-07 19:00 1158

I-Mab Announces Leadership Transitions

ROCKVILLE, Md., July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U....

2024-07-15 19:30 1591

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, g...

2024-06-06 19:00 1329

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

* I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB ...

2024-06-05 19:00 1401

I-Mab to Participate at the Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech comp...

2024-05-22 19:00 1314

I-MAB Filed 2023 Annual Report on Form 20-F

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, ...

2024-04-30 19:00 2814

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech co...

2024-04-05 19:00 1809

I-Mab Announces Closing of the Divestiture of Business Operations in China

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, gl...

2024-04-03 04:01 1565

I-Mab Reports Full Year 2023 Financial Results and Business Update

* Recently announced agreement to divest assets and business operations in China marks an importa...

2024-03-15 05:00 3327

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

* Agreement marks an important milestone to advance the Company's intent to become a U.S.-based b...

2024-02-07 19:00 1547

I-Mab Announces Participation at Jefferies and Piper Conferences in November

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company...

2023-11-06 21:00 1344

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

* FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data...

2023-11-02 20:00 1050

Latest News

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

I-Mab Announces Leadership Transitions

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab to Participate at the Jefferies Global Healthcare Conference

I-MAB Filed 2023 Annual Report on Form 20-F

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab Announces Closing of the Divestiture of Business Operations in China

I-Mab Reports Full Year 2023 Financial Results and Business Update

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

I-Mab Announces Upcoming Participation at September Conferences

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC